VERAXA Biotech Reports New Proof-of-Concept Data for BiTAC-ADC Platform at BIO 2026

VERAXA Biotech (NASDAQ: VRXA) has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company presented the findings as it prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego.

The data demonstrated that VERAXA’s BiTAC-ADC technology could distinguish between breast cancer cells and healthy cells in laboratory studies, showing dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results highlight the potential of VERAXA’s proprietary BiTAC approach to activate therapeutic effects only in targeted tumor cells, sparing healthy tissue.

VERAXA’s BiTAC platform is designed to improve the precision of antibody-based cancer therapies. The company maintains a diversified oncology pipeline of antibody-based formats, including ADCs, T-cell engagers (TCEs), and other antibody-based formats. The newly reported data specifically supports the BiTAC-ADC modality, which aims to enhance the therapeutic index of ADCs by ensuring cytotoxic payloads are released primarily in cancer cells.

The announcement comes as VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The company is now focused on advancing its pipeline and seeking strategic collaborations to further develop its technologies.

At the BIO International Convention 2026, VERAXA is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential partnerships. The company’s presence at the conference is part of a broader effort to attract interest from larger pharmaceutical companies looking for innovative oncology assets. More details about VERAXA’s participation can be found in the company’s announcement.

For the latest news and updates on VERAXA, visit the company’s newsroom at https://ibn.fm/VRXA. For full terms of use and disclaimers, see the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.